Jim Cramer recently gave Eli Lilly a thumbs-up, noting it’s a great time to buy because the stock has dropped significantly.

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Eli Lilly (NYSE:LLY) focuses on researching, developing, and bringing to market a wide range of medicines, including ...

The stock's rise snapped a five-day losing streak.

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $12,357.62 today based on a ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting ...

The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Zacks Research just spiced up Eli Lilly’s Q2 2025 earnings estimate, bumping it to $5.53 per share from $5.48. Other analysts ...